HC Wainwright Predicts Alector’s Q2 Earnings (NASDAQ:ALEC)

Alector, Inc. (NASDAQ:ALEC) – Equities researchers at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for shares of Alector in a report released on Friday, May 8th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($0.22) for the quarter, up from their prior forecast of ($0.37). The consensus estimate for Alector’s current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for Alector’s Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.91) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.95) EPS, FY2029 earnings at ($0.96) EPS and FY2030 earnings at ($0.90) EPS.

Alector (NASDAQ:ALEC) last issued its earnings results on Thursday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The company had revenue of $1.05 million during the quarter, compared to analyst estimates of $9.67 million. Alector had a negative return on equity of 295.17% and a negative net margin of 680.83%.

A number of other brokerages have also issued reports on ALEC. Morgan Stanley restated an “underweight” rating and issued a $2.00 target price on shares of Alector in a research note on Monday, May 4th. Wall Street Zen upgraded Alector from a “sell” rating to a “hold” rating in a research note on Saturday. BTIG Research upgraded Alector from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Tuesday, March 10th. Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a research note on Wednesday, April 15th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alector in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $3.63.

Alector Stock Performance

Shares of ALEC stock opened at $2.05 on Tuesday. The firm has a market capitalization of $227.61 million, a price-to-earnings ratio of -1.72 and a beta of 0.64. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.25 and a quick ratio of 5.25. The business has a fifty day moving average of $2.30 and a 200 day moving average of $1.85. Alector has a 1 year low of $1.01 and a 1 year high of $3.40.

Institutional Investors Weigh In On Alector

Several institutional investors have recently bought and sold shares of ALEC. Vanguard Group Inc. boosted its holdings in shares of Alector by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after purchasing an additional 46,955 shares during the last quarter. Foresite Capital Management IV LLC acquired a new position in shares of Alector during the 4th quarter worth approximately $6,064,000. 683 Capital Management LLC boosted its holdings in shares of Alector by 235.0% during the 4th quarter. 683 Capital Management LLC now owns 3,350,000 shares of the company’s stock worth $5,226,000 after purchasing an additional 2,350,000 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Alector during the 4th quarter worth approximately $5,094,000. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Alector by 76.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,173,202 shares of the company’s stock worth $3,390,000 after purchasing an additional 942,228 shares during the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.